12 Nov. 2024 J. Molner AS launches Lidocaine HCL Topical Solution USP, 4% in the United States
22 Oct. 2024 J. Molner Announces New Chief Financial Officer
17 Sep. 2024 J. Molner AS Consolidated interim report for the first 6 months of 2024 (unaudited)
2 Sep. 2024 J. Molner Announces New President North America at The J. Molner Company LLC
7 Nov. 2022 Pharmaceutical company J. Molner raised about 700,000 euros in the IPO
27 Oct. 2022 J. Molner Introduction Webinar (English)
19 Oct. 2022 IPO of the pharmaceutical company Molner commences on 24 October
06 Oct. 2022 J. Molner submits first drug to Health Canada
Annual Meeting of Shareholders 2024
Report of the Supervisory Board Regarding Financial Year 2023
Supervisory Board Resolution
J. Molner AS Consolidated Annual Report 2023
J. Molner AS annual general meeting of shareholders management board resolution 2023 (EE)
J.Molner AS annual general meeting electronic voting form 2023
J.Molner AS annual general meeting power of attorney form 2023
J. Molner AS voting protocol of shareholders' decisions
Annual Meeting of Shareholders 2023
Notice of Annual Meeting (EE, EN)
Resolution of Management Board (EE)
Agenda of the Annual Meeting and Supervisory Board's recommendations (EE/EN)
Report of the Supervisory Board regarding financial year 2022 (EE/EN)
Power of Attorney Form (EE, EN)
Ballot and Instructions for Electronic Voting (EE, EN)
